Zobrazeno 1 - 10
of 17
pro vyhledávání: '"N. Lezghed"'
Publikováno v:
Annals of Oncology. 33:S580
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9a9d3b9dcfc94ef90d886cc07e4a5d8
https://doi.org/10.1016/j.annonc.2022.07.123
https://doi.org/10.1016/j.annonc.2022.07.123
Autor:
F. Dhermain, Sarah Dumont, François Lemare, M. Pons, N. Lezghed, S. Oinino, May Abbas, Mohamed Khettab, J. Legendre, Delphine Mathivon, Marilene Guillet, Adeline Duflot-Boukobza, M. Di Palma, V. Puglisi, Olivier Mir, Marie Ferrua, Aude Fourcade, Étienne Minvielle
Publikováno v:
Annals of Oncology. 31:S1372
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::167efab0af3fc818f90665d9b482effe
https://doi.org/10.1016/j.annonc.2020.10.329
https://doi.org/10.1016/j.annonc.2020.10.329
Autor:
Pamela Abdayem, Baptiste Abbar, Sophie Bockel, Sarah Dumont, Steven Knafo, Kevin Bourcier, A. Simonaggio, Nicolas Epaillard, Lyna Benadhou, N. Lezghed, Gabriel Garcia, Johan Pallud, Frédéric Dhermain, Lauren Seknazi, Edouard Dezami, Nassim Hammoudi, Razvan Copaciu, Samy Ammari, Guillaume Louvel, Matthieu Faron
Publikováno v:
Neuro Oncol
PURPOSE Although the standard of initial treatment is well defined for glioblastoma, no recommendation exists in the relapse setting. This work focuses on the optimal strategy for recurrent glioblastoma. METHODS Retrospective monocentric analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c12ab1826074332635757df9361333
https://doi.org/10.1093/neuonc/noaa215.135
https://doi.org/10.1093/neuonc/noaa215.135
Autor:
Larisa Martanovschi, Fekih Mahmoud, Guillaume Louvel, Emeline Colomba, Johan Pallud, Julien Domont, Elie El Rassy, Cristina Smolenschi, Frédéric Dhermain, Razvan Copaciu, Edouard Dezamis, Mohamed Kettab, Sophie Bockel, Bianca Cheaib, Sarah Dumont, Samy Ammari, N. Lezghed, Steven Knafo, Gabriel Garcia
Publikováno v:
Neuro Oncol
Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cbca5dfc2576a3d48588dd52796cd6d
https://doi.org/10.1093/neuonc/noaa215.558
https://doi.org/10.1093/neuonc/noaa215.558
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yungan Tao, N. Lezghed, Cécile Michel, M. Debbah, Frederic Deschamps, L. Mayache-Badis, Joël Guigay, François Janot, Caroline Even, Esma Saada-Bouzid
Publikováno v:
Oral oncology. 68
Background Cetuximab, an anti-EGFR monoclonal antibody in combination with platinum and 5FU is the standard of care in first-line treatment of patients with recurrent head and neck squamous cell carcinoma (HNSCC), with an expected median outcome of 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d383e7cedb25c20e69d0dccaa10f551
https://pubmed.ncbi.nlm.nih.gov/28347701
https://pubmed.ncbi.nlm.nih.gov/28347701
Autor:
N. Lezghed, M. Sroussi, A.M. Grecea, Olivier Mir, M. Velev, S. Akla, S. De Percin, M.A. Benderra, P. Terrier, A. Le Cesne, Charles Honoré, L. Haddag, Matthieu Faron, C. Le Pechoux, Sarah Dumont
Publikováno v:
Annals of Oncology. 29:viii589-viii590
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::286fb65af5b6794128ee0335cdbd1064
https://doi.org/10.1093/annonc/mdy299.040
https://doi.org/10.1093/annonc/mdy299.040
Autor:
Margarida Matias, M. Iacob, V. Palomar, Charles Ferté, N. Lezghed, C. Leibu, L. Mayache-Badis, P. Bravo, Caroline Even, M. Annereau
Publikováno v:
Annals of Oncology. 27:vi335
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9af6e91368450e44b12e202e1514c06
https://doi.org/10.1093/annonc/mdw376.23
https://doi.org/10.1093/annonc/mdw376.23
Autor:
L. Mayache-Badis, F.R. Ferrand, Anne Auperin, A. Schilf, Joël Guigay, François Janot, Caroline Even, François Bidault, Stéphane Temam, N. Lezghed, B. Bobillot
Publikováno v:
Annals of Oncology. 25:iv344
Aim: According to the ESMO guidelines, 5FU, platinum and cetuximab is the standard in first line for patients (pts) with R/M SCCHN (PFEx; Vermorken, 2008). In 2012, the multicenter phase II TPEx GORTEC 2008-03 evaluating TPEx (4 cycles (cy) and maint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80d13d5691277bbe911cf99ab7d12872
https://doi.org/10.1093/annonc/mdu340.12
https://doi.org/10.1093/annonc/mdu340.12
Autor:
Laurent Levy, Philippe Terrier, Antoine Italiano, Axel Le Cesne, N. Lezghed, Stöckle E, M. Antoine, Nathalie Lassau, Eric Deutsch, Sylvie Bonvalot, Thierry de Baere, Paul Sargos, Jean-Charles Soria, Fouzia Azzouz, Xavier Buy, Borghi Elsa, Mikaela Dimitriu, Cécile Le Péchoux, Alejandro Goberna
Publikováno v:
Journal of Clinical Oncology. 32:10563-10563
10563 Background: Functionalized hafnium oxide nanoparticles (NBTXR3) have been developed as selective radioenhancers, which may represent a breakthrough approach for the local treatment of solid t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8437603449d9fdd98c051873141c1ad4
https://doi.org/10.1200/jco.2014.32.15_suppl.10563
https://doi.org/10.1200/jco.2014.32.15_suppl.10563